Wet Age-Related Macular Degeneration

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related macular degeneration.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for OTX-TKI, a tyrosine kinase inhibitor designed to block VEGFR-1, VEGFR-2 and VEGFR-3.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses recent breakthroughs demonstrating that gene therapy is a viable option for treating wet age-related macular degeneration.

Healio spoke with Nathan M. Radcliffe, MD, about disparities that exist in glaucoma care.

Healio spoke with Nathan M. Radcliffe, MD, about the best practices for monitoring glaucoma progression.

Healio spoke with Nathan M. Radcliffe, MD, about the evolution of glaucoma care.

Healio spoke with Nathan M. Radcliffe, MD, about exciting new advancements in the treatment of glaucoma.

Healio spoke with Nathan M. Radcliffe, MD, about discussing treatment options for glaucoma with patients.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, shares phase 2 data investigating Duravyu for wet age-related macular degeneration treatment vs. aflibercept.